L. Lévy-Bachelot

548 total citations
49 papers, 393 citations indexed

About

L. Lévy-Bachelot is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Economics and Econometrics. According to data from OpenAlex, L. Lévy-Bachelot has authored 49 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pediatrics, Perinatology and Child Health and 9 papers in Economics and Econometrics. Recurrent topics in L. Lévy-Bachelot's work include Health Systems, Economic Evaluations, Quality of Life (9 papers), Epilepsy research and treatment (7 papers) and Pharmacological Effects and Toxicity Studies (6 papers). L. Lévy-Bachelot is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (9 papers), Epilepsy research and treatment (7 papers) and Pharmacological Effects and Toxicity Studies (6 papers). L. Lévy-Bachelot collaborates with scholars based in France, United States and United Kingdom. L. Lévy-Bachelot's co-authors include C. Chouaïd, Vicente Villanueva, E. Clay, Manuel J. Cuesta, Juan José Lahuerta, Javier Martín‐Broto, A. Millier, Min Huang, Pierre Lévy and B. Detournay and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Vaccine.

In The Last Decade

L. Lévy-Bachelot

48 papers receiving 393 citations

Peers

Countries citing papers authored by L. Lévy-Bachelot

Since Specialization

Citations

This map shows the geographic impact of L. Lévy-Bachelot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Lévy-Bachelot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Lévy-Bachelot more than expected).

Fields of papers citing papers by L. Lévy-Bachelot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Lévy-Bachelot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Lévy-Bachelot. The network helps show where L. Lévy-Bachelot may publish in the future.

Co-authorship network of co-authors of L. Lévy-Bachelot

This figure shows the co-authorship network connecting the top 25 collaborators of L. Lévy-Bachelot. A scholar is included among the top collaborators of L. Lévy-Bachelot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Lévy-Bachelot. L. Lévy-Bachelot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hospital costs of Balloon Pulmonary Angioplasty (BPA) procedure and management for CTEPH patients: An observational study based on the French national hospital discharge database (PMSI) 2021 ·PLoS ONE ·Vincent Cottin, (unknown), F. Raguideau, (unknown), (unknown), L. Lévy-Bachelot, Alexandre Vainchtock, Jean Dallongeville, Hélène Bouvaist, Philippe Brénot	2
2	Human papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study 2021 ·Vaccine ·(unknown), (unknown), Manon Belhassen, (unknown), (unknown), L. Lévy-Bachelot, Gérard de Pouvourville, Roman Rouzier, Jocelyn Raude, Jean‐Jacques Baldauf	6
3	Real-world evaluation of ceftolozane/tazobactam therapy and clinical outcomes in France 2021 ·Infectious Diseases Now ·Bernard Castan, (unknown), L. Lévy-Bachelot, (unknown), (unknown), (unknown), (unknown), Joy Mootien, Raymond Ruimy, Fabrice Ruiz, Jean‐François Timsit, David Boutoille	7
4	Overview of French databases available for studying anticancer drugs in real‐life setting 2020 ·Fundamental and Clinical Pharmacology ·(unknown), Pernelle Noïze, Amandine Gouverneur, Driss Berdaï, Bernard Bégaud, L. Lévy-Bachelot, Mathiéu Molimard	8
5	PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France 2020 ·Value in Health ·C. Chouaïd, (unknown), (unknown), A. Millier, (unknown), Ashutosh Rai, L. Lévy-Bachelot, Pierre Lévy	1
6	Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database 2020 ·Diabetes Therapy ·Corinne Emery, (unknown), S. Dejager, L. Lévy-Bachelot, (unknown), B. Detournay	5
7	Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients 2019 ·Joint Bone Spine ·Bruno Fautrel, Manon Belhassen, Christophe Hudry, Marie-Christine Woronoff-Lemsi, L. Lévy-Bachelot, Éric Van Ganse, Florence Tubach	3
8	CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50%) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCE 2018 ·Value in Health ·C. Chouaïd, (unknown), E. Clay, A. Millier, L. Lévy-Bachelot, Min Huang, Pierre Lévy	1
9	Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France 2018 ·Lung Cancer ·C. Chouaïd, (unknown), E. Clay, A. Millier, L. Lévy-Bachelot, Min Huang, Pierre Lévy	53
10	Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis 2017 ·PharmacoEconomics - Open ·B Charbonnel, Dominique Simon, Jean Dallongeville, I. Bureau, S. Dejager, L. Lévy-Bachelot, J. Gourmelen, B. Detournay	32
11	P1.06-044 Costs of Adverse Events (AE) Associated with Cancer Therapies in Non-Small Cell Lung Cancer (NSCLC) in France 2017 ·Journal of Thoracic Oncology ·C. Chouaïd, Delphine Loirat, (unknown), E. Clay, A. Millier, L. Lévy-Bachelot, Eric Angevin	1
12	Excess mortality between 2007 and 2014 among patients with Clostridium difficile infection: a French health insurance database analysis 2017 ·Journal of Hospital Infection ·Frédéric Barbut, S. Bouée, (unknown), Marcel Goldberg, (unknown), L. Lévy-Bachelot	13
13	Coût des consommations de soins après un infarctus du myocarde en France : une estimation à partir de l’échantillon généraliste des bénéficiaires (EGB) 2017 ·Annales de Cardiologie et d Angéiologie ·Philippe François, Patrick Blin, S. Bouée, (unknown), (unknown), (unknown), (unknown), L. Lévy-Bachelot, Philippe Gabríel Steg	5
14	Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis 2016 ·International Journal of Cardiology ·Patrick Blin, Philippe François, S. Bouée, (unknown), (unknown), (unknown), S. Leproust, L. Lévy-Bachelot, Philippe Gabríel Steg	22
15	Cost-Effectiveness of Pembrolizumab for Treating Previously Untreated Metastatic Melanoma Patients in France 2016 ·Value in Health ·(unknown), (unknown), A. Gauthier, L. Lévy-Bachelot, (unknown)	1
16	Patterns of Pharmacological Treatment in Type 2 Diabetes in France in 2013 2015 ·Value in Health ·D. Simon, Jean Dallongeville, B Charbonnel, I. Bureau, B. Detournay, S. Leproust, L. Lévy-Bachelot, J. Gourmelen	3
17	Coût du lupus systémique en France des patients adultes avec une maladie active et traitée (étude LUCIE) 2014 ·La Revue de Médecine Interne ·Zahir Amoura, C. Deligny, (unknown), M. Hamidou, Patrick Blanco, É. Hachulla, Jacques Pourrat, V. Queyrel, A. Garofano, Frédérique Maurel, L. Lévy-Bachelot, I. Boucot	2
18	Management of focal epilepsy in adults treated with polytherapy in France: The direct cost of drug resistance (ESPERA study) 2014 ·Seizure ·(unknown), Bertrand de Toffol, Hervé Vespignani, (unknown), L. Lévy-Bachelot, (unknown), Francis Fagnani	17
19	Abacavir (Ziagen®) use between 2003 and 2008 in France according to the electronic medical record NADIS® 2013 ·Médecine et Maladies Infectieuses ·P. Dellamonica, Christine Katlama, L. Lévy-Bachelot, J.P. Daurès, Laurent Finkielsztejn	2
20	PMH70 Economic Impact of Focal Epilepsy in Spain: Results of the Espera Study 2011 ·Value in Health ·Vicente Villanueva, Max Brosa, (unknown), (unknown), L. Lévy-Bachelot, Juan José Lahuerta, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact